Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, specializing in the development of innovative therapies for central nervous system (CNS) disorders with substantial unmet needs. The company is advancing a dynamic clinical pipeline that emphasizes pain management and neurological conditions, utilizing state-of-the-art research techniques to discover and develop novel drug candidates. Trevena’s strategic focus on improving patient outcomes positions it to make significant contributions to the CNS therapeutics market, navigating the complexities of drug development and commercialization in the process. Show more

Location: 955 CHESTERBROOK BOULEVARD, CHESTERBROOK, PA, UNITED STATES, 19087, Chesterbrook, PA, 19087, USA | Website: https://www.trevena.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

9.50K

52 Wk Range

$0.00 - $1.93

Previous Close

$0.01

Open

$0.01

Volume

Day Range

$0.01 - $0.01

Enterprise Value

24.11M

Cash

13.46M

Avg Qtr Burn

-4.503M

Insider Ownership

0.49%

Institutional Own.

9.98%

Qtr Updated

09/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OLINVYK™ (oliceridine) Details Pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRV250 (Delta receptor agonist) Details Migraines	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRV045 (S1P receptor) Details Epilepsy, Central nervous system illness, Pain	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRV734 (Mu receptor agonist) Details Opioid use disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRV027 (AT1 receptor selective agonist) Details Acute respiratory distress syndrome, Infectious disease, COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.